Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours) + Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours) + Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Conditions
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Trial Timeline
Oct 30, 2026 → May 20, 2028
NCT ID
NCT06801223About Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours) + Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours) + Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)
Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours) + Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours) + Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours) is a phase 1 stage product being developed by Innoviva for Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06801223. Target conditions include Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC).
Hype Score Breakdown
Clinical
6
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06801223 | Phase 1 | Recruiting |